The loss of smell is a common symptom in LBD, Parkinson’s disease and even Alzheimer’s disease. New research suggests the loss of smell in Parkinson’s disease (PD) may help predict […]

This week Axovant Sciences released preliminary results for one of its LBD clinical trials of an experimental medication, nelotanserin. The first eleven people with LBD have completed the Phase 2 […]

The rate of progression in Lewy body dementia (LBD) is hard to predict at the time of diagnosis. New research indicates the presence of a second neurodegenerative disease process, Alzheimer’s […]

We are entering an era of unprecedented opportunity for understanding and treating Lewy body dementia (LBD). Our newest white paper, Lewy Body Dementia: The State of the Science provides the […]

Goals of Care | First-Line Medications | Other Drugs to Avoid Download this article as a PDF The importance of early treatment is supported by recent data suggesting that patients […]

Lewy body pathology (presence of Lewy bodies in the brain)  is found in up to 50% of cases of late-onset Alzheimer’s disease, which can make it challenging for physicians to […]

Dementia is often preceded by an earlier phase called mild cognitive impairment (MCI), where an individual is still able to live independently, but notices changes in at least one area […]

Drowsiness and daytime sleepiness (despite getting adequate sleep the night before) are often described by individuals with dementia with Lewy bodies (DLB) and their caregivers. This is reported even in […]

By Carol Bradley Bursack A new study by Ohio State University in conjunction with the National Institute on Aging has shown that adult children caring for their parents, as well […]

A new study reveals family caregivers have an increase in the beneficial stress hormone DHEA-S on days when they use an adult day service for their relatives with dementia. DHEA-S […]